JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma

This study tests a combination of two immunotherapy drugs — JS207 and JS007 — as a first treatment option for people with advanced liver cancer (hepatocellular carcinoma, or HCC) that cannot be removed by surgery. Researchers want to see if this drug combination is effective and safe for patients who have not yet had systemic (whole-body) drug treatment. **You may be eligible if...** - You are 18 or older with confirmed advanced liver cancer (HCC) - Your cancer has been classified as intermediate or advanced stage and cannot be treated with surgery or local procedures - You have not previously received systemic drug therapy for liver cancer - Your liver is functioning reasonably well (Child-Pugh class A or B with a score of 7 or less) - You have at least one measurable tumor **You may NOT be eligible if...** - You have received prior immunotherapy or targeted therapy for liver cancer (except for certain drugs used after surgery, if stopped at least 90 days before) - Your liver function is significantly impaired - You have active autoimmune disease or certain other serious health conditions Talk to your doctor to see if this trial is right for you.